

# Profile of the patients treated by apremilast in a prospective non-interventional, descriptive, multicenter study in France: first results

A.-C. Fougousse , D. Bouilly-Auvray, M. Bastien, R. Safar, C. Girard, E. Begon, M. Perrussel, M. Zeitoun, J.-B. Monfort, C. Jacobzone, P. Pfister, E. Mahé, V. Pallure, D. Thomas-Beaulieu, B. Solyga, F Maccari, for the GEM Resopso

**Introduction:** Apremilast was commercialized in France in October 2016. Real-life data are needed to complete efficacy and safety profile

**Methods:** We performed a non-interventional, descriptive, multicenter study in 16 French dermatology centers. We included all adults who was started apremilast for plaque psoriasis from May 2018. The protocol included demographic informations, disease duration, clinical characteristics and severity of psoriasis, previous treatments, associated comorbidities, smoking status. Severity of psoriasis was evaluated with PASI, PGA and DLQI. Montgomery-Asberg depression rating scale (MADRS) was used to assess depression. One year inclusion and 2 years follow up are scheduled. We present here the first patient's characteristics at inclusion.

**Results:** In women, mean age was 49.2 years; mean PASI, PGA and DLQI were respectively 12.7, 2.5 and 20.7. In men, mean age was 69.2 years; mean PASI, PGA and DLQI were respectively 12.7, 2.8 and 17.2.

**Discussion:** Inclusion characteristics of our patients are comparable with those of other real-life studies concerning apremilast.

Table 1 Demographic data and psoriasis characteristics at inclusion

	n=62
Gender (male)	n=33 (53.2%)
Age (mean)	59.8 years
Psoriasis age of onset (mean)	32.9 years
Psoriasis type	
- Plaques generalized	n=40 (56.4%)
- Palmo-plantar plaques	n=10 (16.1%)
- Plaques localized	n=15 (24.2%)
- Small plaques	n=7 (11.3%)
Psoriatic arthritis	n= 3 (4.8%)
BMI (mean)	27.3
Comorbidities	
Hypertension	n=20 (32.2%)
Dyslipidemia	n=18 (29%)
Current smoking	n=18 (29%)
Diabetes	n=9 (15.4%)
Alcohol abuse	n=7 (11.3%)
Previous systemic treatments	
None	n=22 (35.5%)
Phototherapy	n= 23 (37%)
Retinoids	n=18 (29%)
Methotrexate	n=14 (22.5%)
Cyclosporin	n=3 (4.8%)
Etanercept	n=2 (3.2%)
Severity of psoriasis at initiation	
PASI (mean)	10.9
PGA (mean)	2.7
DLQI (mean)	18.8
MADRS (mean)	5.4

**Conclusion:** Follow up data will enable us to assess tolerance, efficacy and drug survival of apremilast in real life.